JOBEN BIO-MEDICAL CO., LTD.
Update：2026/08/06
Industries
Main Industry
Biotechnology
Main Product/Service
1. Supercritical Fluid Extraction (SFE) Technology Platform
2. Patent and herbal new botanical drug development
3. Antrodia cinnamomea product development
4. Accredited inspection body
2. Patent and herbal new botanical drug development
3. Antrodia cinnamomea product development
4. Accredited inspection body
Founded Year
2010
Unified Business No.
29184631
Status
Active
Number of Employees
0
Total Paid-in
Capital
676,159,700 (NT$)
Location of Company
Taiwan
, Pingtung County
Exit Status
Emerging Stock Exchange(2015)
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
By using our core technologies on natural Chinese herbal medicine, Joben Bio-Medical has successfully developed the new botanic drug JBM-TC4 (patent protection pending), which was approved by U.S. FDA-Phase II for clinical trial in March 2013, and approved by TFDA for phase II clinical trial in May When the new botanic drug JBM-TC4 is successfully developed, it will offer cancer patients all over the world more options for treating cancer effectively. A botanic drug with compound ingredients can be used with the small molecule drug of a single ingredient, and this will be a major trend for the integrated treatment of cancer in the future, for it not only can assist and increase the anti-cancer treatment, but also reduce the side effects brought about by the small molecule drug of a single ingredient. This is very significant, for it increases the living quality of the cancer patients by reducing the side effects of treatment.
Our R&D teams fully use the present core technologies and original materials to develop new botanic drugs according to the schedule of our new biotech drugs project. In July 2013, Joben Bio-Medical was approved by MOEA to be a biotech new drug company.
Our R&D teams fully use the present core technologies and original materials to develop new botanic drugs according to the schedule of our new biotech drugs project. In July 2013, Joben Bio-Medical was approved by MOEA to be a biotech new drug company.
